The present work investigated the effects of Norplant implants on the pituitary-adrenal function among 15 users of Norplant implants prior to and 6 months after insertion of the implants. Serum cortisol levels and their diurnal variations, ACTH and 24-h urinary 17-ketosteroids, ketogenic steroids, 17-hydroxy steroids, and creatinine, were measured. Also, a dynamic test (the 5-h Synacthen depot = ACTH stimulation test) was done before and 6 months after implants insertion. The 9 a.m. cortisol levels were blunted (within the normal ranges) while the 6 p.m. values were unaltered. The 24-h urinary ketogenic, hydroxy, and ketosteroids were also unchanged after Norplant implants use. The ACTH stimulation test showed a decreased adrenal response which was also within normal ranges. These data should raise the question related to suprarenal response to acute or prolonged stresses, such as surgical operations or shock in women using Norplant implants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0010-7824(96)00241-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
J Natl Cancer Inst
January 2025
School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia.
Background: Use of long-acting, reversible contraceptives has increased over the past 20 years, but an understanding of how they could influence cancer risk is limited.
Methods: We conducted a nested case-control study among a national cohort of Australian women (n = 176 601 diagnosed with cancer between 2004 and 2013; 882 999 matched control individuals) to investigate the associations between the levonorgestrel intrauterine system, etonogestrel implants, depot-medroxyprogesterone acetate and cancer risk and compared these results with the oral contraceptive pill. We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI).
Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices.
Hematology Am Soc Hematol Educ Program
December 2024
Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Hormonal contraceptive therapy (estrogens and/or progestogens) includes different formulations associated with varying venous thromboembolism (VTE) risks. The thrombogenicity of combined hormonal contraceptives (CHCs) is due at least in part to multiple changes in clotting factors and the vasculature and is dependent on both estrogen dose and type of progestin. Transdermal patch and vaginal ring users have similar or higher VTE risk as combined oral contraceptive users.
View Article and Find Full Text PDFTips and tricks for the management of contraceptive etonogestrel implant in clinical practice: an Expert Opinion.
Eur J Contracept Reprod Health Care
December 2024
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Article Synopsis
- The global use of long-acting reversible contraceptives (LARCs) is rising because they more effectively prevent unintended pregnancies compared to short-acting methods, especially in teens.
- LARCs include options like intrauterine devices and subcutaneous implants, with specialized training required for their application.
- This Expert Opinion focuses on the etonogestrel (ENG)-releasing implant, offering updated guidance on insertion, removal, and managing unscheduled bleeding based on extensive clinical experience.
Menstrual Suppression in Gender-Diverse Youth: What's Most Important to Patients?
J Pediatr Adolesc Gynecol
November 2024
Nationwide Children's Hospital, Division of Adolescent Medicine, Columbus, Ohio; Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio; The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Study Objective: To explore reasons for menstrual suppression method choice among transgender and gender-diverse (TGD) youth at the time of method initiation DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional analysis of baseline data from a prospective cohort study of menstruating TGD youth (N = 55), aged 12-17 years, initiating a hormonal method for menstrual suppression in a gender health specialty clinic at a single site, quaternary hospital in the Midwest INTERVENTIONS AND MAIN OUTCOME MEASURES: Participants completed a baseline survey that included identifying the most important reason, as well as other important reasons, for menstrual suppression method selection.
Results: The mean age was 14.9 (SD 1.
Risk of early etonogestrel and levonorgestrel implant discontinuation in adolescents and adults.
BMC Public Health
November 2024
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, 1873 Rama IV Road, Patum Wan, Patum Wan, Bangkok, 10330, Thailand.
Article Synopsis
- Etonogestrel and levonorgestrel contraceptive implants are effective for 3 and 5 years, respectively, but early removal before due date can lead to unintended pregnancies, particularly among adolescents.
- A study conducted at King Chulalongkorn Memorial Hospital analyzed early implant discontinuation from 2014 to 2019, finding a 19.3% overall discontinuation rate with intolerance to side effects, like abnormal bleeding, being the main reason for removal.
- Results indicated that adolescents had a lower likelihood of early discontinuation than adults, with factors such as free implants, continuous use, postpartum status, and having children contributing to reduced discontinuation rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!